Immunotherapy is the use of components of the immune system (antibodies, citokines, dendritic cells, etc.) in medicine, for the treatment of several illnesses such as cancer, allergy, autoimmune and infectious diseases. Immunotherapy also includes the use of vaccines in the prevention of infectious diseases or in the treatment of allergies or tumours. Immunotherapy may add new dimensions to the clinic, new ways of cure, with clear beneficial effects such as lower secondary effects, higher efficacy and better tolerance than other medicines.

One research focus in our group is to generate innovative therapeutic agents. In this sense, we have obtained antigen specific fully human monoclonal antibodies (huMoAb) using genetically engineered mice and hybridoma technology.

Particularly, we could highlight:

  • BH1, a huMoAb that recognizes the molecule HLA-class II.  BH1 could be a good candidate as a therapeutic agent for the treatment of different HLA-class II positive leukaemias and other malignancies.
  • h-AIM29, this huMoAb is specific for the human CD69 molecule. Some of its potential clinical application is for patients with arthritis or even with those with cancer.
  • Several huMoAb directed to human B and monocytes cells.

Projects in this research line: